Neurotoxicity of chemotherapeutic agents after blood‐brain barrier modification: Neuropathological studies

Annals of Neurology

Volumn 14, Issue 3, 1983, Pages 316-324

  Neuwelt, Edward A ^a,c   Glasberg, Mark ^b   Frenkel, Eugene ^c,d   Barnett, Peggy ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c University of Texas Southwestern   (United States)

^d Veterans Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MANNITOL;

BIOLOGICAL MODEL; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN NECROSIS; CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY; DOG; HISTOLOGY; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; NERVOUS SYSTEM; NEUROTOXICITY; NONHUMAN; PHARMACOKINETICS;

ANIMAL; ANTINEOPLASTIC AGENTS; BLEOMYCIN; BLOOD-BRAIN BARRIER; BRAIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLUOROURACIL; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MANNITOL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0020592356     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410140310     Document Type: Article

References (39)

1. The effects of cancer therapy on the nervous system
2. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma
3. Leukoencephalopathy following high dose intravenous methotrexate chemotherapy: quantitative assessment of white matter attenuation using computer tomography
4. Seizures and transient cortical blindness associated with cis‐platinum (11) diamminedichloride (PDD) therapy in a thirty‐year‐old man
5. Kinetics of entry and distribution of 5‐fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate
6. Phase 1‐11 trial of percutaneous intra‐arterial cis‐diamminedichloroplatinum for regionally confined malignancy
7. The clinical pharmacology of antineoplastic agents (first of two parts)
8. Neurotoxicity of cis‐platinum: pathology of the central and peripheral nervous systems
9. Bleomycin therapy and cytotoxicity
10. Irradiation, methotrexate toxicity and the treatment of meningeal leukemia
11. Paraplegia following intrathecal methotrexate
12. Metabolism of radioactive cyclophosphamide
13. Peripheral neuropathy associated with cis‐dichlorodiammineplatinum treatment
14. Neurotoxicity of antineoplastic drugs
15. Encephalopathy in acute leukemia associated with methotrexate therapy
16. Biochemical basis for fluorouracil neurotoxicity
17. Methotrexate encephalopathy
18. Organic brain syndrome: secondary to 5‐fluorouracil toxicity
19. Neurotoxicity of Adriamycin (doxorubicin) perfused through the cerebrospinal fluid spaces of the rhesus monkey
20. The effects of osmotic modification of the blood brain barrier and adrenal steroid administration on methotrexate delivery of gliomas in rats: the blood brain barrier is a factor
21. Is there a therapeutic role for blood brain barrier disruption?
22. Reversible osmotic blood brain barrier disruption in humans: implications for the chemotherapy of malignant brain tumors
23. Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood‐brain barrier disruption
24. Effect of osmotic blood‐brain barrier disruption on methotrexate pharmacokinetics in the dog
25. Use of enhanced computerized tomography to evaluate osmotic blood brain barrier disruption
26. Osmotic blood brain barrier disruption: computerized tomographic monitoring of chemotherapeutic agent delivery
27. The pharmacology and toxicity of intracarotid Adriamycin administration following osmotic blood brain barrier modification
28. Neurotoxicity from 5FU (NSC‐19893) administration reproduced by mitomycin C (NSC‐26980)
29. Hemorrhagic encephalitis produced by selective non‐occlusive intracarotid BCNU injection in dogs
30. Chronic effects of osmotic opening of the blood‐brain barrier in the monkey
31. Quantitative aspects of reversible osmotic opening of the blood‐brain barrier
32. Osmotic opening of the blood‐brain barrier in the rhesus monkey without measurable brain edema
33. 14sucrose after osmotic opening of the blood‐brain barrier
34. Acute cerebellar syndrome secondary to 5‐FU therapy
35. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma
36. Necrotizing encephalopathy following instillation of methotrexate
37. A phase 1 study of intracarotid artery infusion of cis‐diamminedichloroplatinum in patients with recurrent malignant intracerebral tumors
38. The metabolic fate of cyclophosphamide